Clinical trial
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer
NCT00148070 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00148070 |
|---|---|
| Title | Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer |
| Official title | Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | Aventis Pharmaceuticals Industry Rhone-Poulenc Rorer |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Docetaxel, Erythromycin Breath Test (ERMBT) |
| Enrollment | 45 |
| Start date | Mar 1, 1999 |
| Primary completion | Sep 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Sep 7, 2005 |
| Last update posted | Oct 5, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: